Latest news with #SharvilPatel
Time of India
4 days ago
- Business
- Time of India
Zydus Lifesciences Q1 net profit rises 3% to Rs 1,467 crore
Zydus Lifesciences on Tuesday said its consolidated net profit increased 3 per cent year-on-year to Rs 1,467 crore for the first quarter ended June 30, 2025, riding on strong performance across domestic and international markets. The drug maker reported a net profit of Rs 1,420 crore for the April-June quarter of the last fiscal. Revenue from operations rose to Rs 6,574 crore for the June quarter as compared with Rs 6,207 crore in the year-ago period, the drug maker said in a statement. "Our Q1 FY2026 performance reflects the results of our disciplined execution, with most of our key businesses meeting expectations," Zydus Lifesciences MD Sharvil Patel said. The company remains firmly on track to achieve FY2026 aspirations and is excited about the upcoming developments on the innovation front, which will open up new avenues for sustainable growth, he added. The drug maker said its domestic business revenue increased 6 per cent year-on-year to Rs 2,374 crore in the June quarter. Revenues of the formulations business saw a growth of 8 per cent year-on-year to Rs 1,519 crore in the year-ago period. by Taboola by Taboola Sponsored Links Sponsored Links Promoted Links Promoted Links You May Like Original Adidas Three Combo Track-Pants With Up To 60% Off Adidas India Shop Now Undo Consumer wellness business revenue grew 2 per cent year-on-year to Rs 855 crore in the first quarter ended June 30, 2025. US formulations business revenue grew 3 per cent year-on-year to Rs 3,182 crore in the June quarter. Shares of the company on Tuesday ended 0.27 per cent up at Rs 958.05 apiece on BSE. Stay informed with the latest business news, updates on bank holidays , public holidays , current gold rate and silver price .
&w=3840&q=100)
Business Standard
4 days ago
- Business
- Business Standard
Zydus Lifesciences Q1 PAT up 5.9% on strong India, int'l formulations biz
Ahmedabad-based Zydus Lifesciences on Tuesday reported a 5.9 per cent year-on-year (Y-o-Y) increase in consolidated net profit for the June quarter (Q1FY26) to ₹1,466 crore, up from ₹1,419 crore in the same quarter last year. Revenue from operations rose 3.3 per cent Y-o-Y to ₹6,573 crore in Q1FY26 from ₹6,207 crore in Q1FY25. The growth was driven by strong performances in the company's domestic and international formulations segments, even as its consumer wellness and US businesses saw muted growth. In Q1FY26, the India formulations business grew 5.8 per cent Y-o-Y to ₹2,374 crore, with the company stating that its branded formulations segment outperformed the market in both chronic and acute categories. The international markets formulations business posted a 36.8 per cent Y-o-Y increase to ₹726.5 crore, while the active pharmaceutical ingredients (API) segment rose 11.3 per cent to ₹157.5 crore. 'All-round growth across key geographies was driven by strong demand and focused execution,' Zydus said in a filing to the exchanges. The US market, which contributes 49 per cent of consolidated revenue, saw only a 2.9 per cent Y-o-Y increase to ₹3,181 crore, despite the launch of three new products during the quarter. The consumer wellness business, contributing 13 per cent to consolidated revenue, grew 2 per cent Y-o-Y to ₹854.9 crore, with performance impacted by seasonal brands. However, the company said its core wellness brands posted strong double-digit growth, reflecting the underlying strength of its portfolio and balanced business model. Commenting on the results, Sharvil Patel, Managing Director of Zydus Lifesciences, said the Q1 performance reflected disciplined execution, with most key businesses meeting expectations. 'We remain firmly on track to achieve our FY26 aspirations and are excited about the upcoming developments on the innovation front, which we believe will open up new avenues for sustainable growth,' Patel added. On Tuesday, Zydus Lifesciences shares closed flat with a 0.05 per cent rise at ₹956 apiece on the Bombay Stock Exchange (BSE).
Mint
4 days ago
- Business
- Mint
Zydus Life beats Street in Q1, eyes biosimilars boost in US
Zydus Lifesciences beat Street estimates in the June quarter on the back of steady India growth, a stronger US portfolio, and surging international sales. This sets the stage for its biosimilars push in the world's largest pharmaceuticals market following a $125 million manufacturing acquisition. The Ahmedabad-based drugmaker reported a revenue growth of 6% year-on-year (y-o-y) to ₹ 6,573 crore, and a net profit of ₹ 1,466 crore, up 3%. Its Ebitda was ₹ 2,088 crore, with the margin at 31.8%. A Bloomberg poll had pegged its revenues at ₹ 6,477 crore and profit after tax at ₹ 1,332 crore. In the June quarter, Zydus's India business clocked an 8% y-o-y growth, driven by chronic therapies and innovation-led portfolio expansion. Its US business, the largest revenue driver for the company, grew 2.9%. The company's international business segment, which includes Europe and other emerging markets, grew 36.8% y-o-y on the back of strong demand and has emerged as a 'reliable third pillar of growth,' said Sharvil Patel, the company's managing director. Zydus, which has a significant portfolio of biosimilars in India and other markets, is eyeing growth in the US on the back of easing regulations and a recent acquisition of two US-based two biologics contract manufacturing facilities. '...the regulatory scenario has changed for certain classes of biosimilars, there is no longer a requirement for an efficacy trial. So the pathway has become much better for the US,' Patel told investors in a post-earnings call on Tuesday. 'The second factor is that we have a manufacturing footprint now in the US to make biologics,' he added. The company is looking at either an in-house portfolio or licensing deals with manufacturing firms in the US to add one or two biosimilars, Patel said. Zydus acquired two biologics contract development and manufacturing organization (CDMO) plants in California from US-based Agenus Inc for a total consideration of up to $125 million in June. It also acquired a 5.9% stake in Agenus Inc for $16 million. Agenis is a clinical stage immuno-oncology company committed to developing immune therapies to combat cancer. 'The acquisition marks our strategic investment in the US-based manufacturing for biologics, thereby adding a sustainable growth driver for the future,' Patel said. The company has 14 launched biosimilars and 10 in the pipeline, and a presence in India and as well as in the international markets. Zydus is foraying into new avenues of growth such as medtech, and is also strengthening its specialty business play to unlock value. The company has been enriching its portfolio of 505 b(2) specialty products, which will be a significant profitability driver, going forward, Patel said. 'We already have a decent revenue on 505 b(2) with good profitability, but we are seeing a major scale-up in FY27 and beyond,' he said. 505 b(2) products refer to drug candidates that may be new indications or new combinations, and are approved through the 505 b(2) application, as opposed to an Abbreviated New Drug Application (ANDA) in the US FDA.
News18
4 days ago
- Business
- News18
Zydus Lifesciences Q1 net profit rises 3 pc to Rs 1,467 cr
Agency: PTI New Delhi, Aug 12 (PTI) Zydus Lifesciences on Tuesday said its consolidated net profit increased 3 per cent year-on-year to Rs 1,467 crore for the first quarter ended June 30, 2025. The drug maker reported a net profit of Rs 1,420 crore for the April-June quarter of the last fiscal. Revenue from operations rose to Rs 6,574 crore for the June quarter as compared with Rs 6,207 crore in the year-ago period, the drug maker said in a statement. 'Our Q1 FY2026 performance reflects the results of our disciplined execution, with most of our key businesses meeting expectations," Zydus Lifesciences MD Sharvil Patel said. The company remains firmly on track to achieve FY2026 aspirations and is excited about the upcoming developments on the innovation front, which will open up new avenues for sustainable growth, he added. Shares of the company on Tuesday ended 0.27 per cent up at Rs 958.05 apiece on BSE. PTI MSS MSS DR DR view comments First Published: Disclaimer: Comments reflect users' views, not News18's. Please keep discussions respectful and constructive. Abusive, defamatory, or illegal comments will be removed. News18 may disable any comment at its discretion. By posting, you agree to our Terms of Use and Privacy Policy.
Mint
04-06-2025
- Business
- Mint
Zydus to Enter Global Biologics CDMO Business Plans
New Jersey, United States & Ahmedabad, Gujarat, India – Business Wire India Zydus Lifesciences Ltd. (including its subsidiaries/affiliates, hereafter referred to as 'Zydus) today announced its entry into the global biologics contract development and manufacturing organization (CDMO) business through its plan to acquire Agenus Inc.'s (Nasdaq: AGEN) U.S.-based biologics CMC facilities. This acquisition marks Zydus' strategic investment in U.S.-based manufacturing for biologics thereby adding a sustainable growth driver for the group. Agenus Inc. is a clinical-stage immuno-oncology company committed to developing immune therapies that effectively combat cancer. Under the terms of the agreement, Zydus will acquire two state-of-the-art biologics manufacturing facilities from Agenus in Emeryville and Berkeley, California (US) for an upfront consideration of US$75 million and contingent payment of US$50 million to be paid over three years subject to achievement of certain revenue milestone. This acquisition provides Zydus immediate access to advanced biologics manufacturing capabilities and establishes a key presence in California, a leading global biotechnology hub. This strategic move enables Zydus to leverage supply chain dynamics and a favourable geopolitical environment to expand its reach in the U.S. and globally. With this acquisition Zydus will now become a one stop solution provider across the entire development spectrum of biologics, right from pre-clinical to toxicology studies, clinical development and now CDMO business will operate as an independent entity and will house the acquired manufacturing capabilities. The facilities come with an experienced professional team with strong capabilities and requisite industry expertise to deliver high-quality biologics development and manufacturing services to global biotech and pharmaceutical companies. As a part of transaction Zydus will become an exclusive contract manufacturer for Agenus and will provide manufacturing services for clinical and commercial supply of two identified Phase-3 ready immuno-oncology products, Botensilimab (BOT) and Balstilimab (BAL). Zydus will also have first right of negotiation to manufacture any of the future pipeline products developed by Agenus. Zydus intends to further expand the team and help create new jobs in the region and contribute to the local on the development, Dr. Sharvil Patel, Managing Director, Zydus Lifesciences Ltd. said, "The acquisition will give Zydus a strategic foothold in the U.S. for biologics manufacturing in the global hub for biotech innovation, California. It will enhance our ability to partner with innovation-centric entities, advancing new products and prioritizing patient-centric solutions. This move strengthens our long-term biologics vision and positions us to better serve the evolving needs of the global biopharmaceutical industry." The global biologics CDMO market is experiencing significant growth, driven by the increasing complexity of therapies, the rise of biologics in clinical pipelines, and a growing number of emerging biotech companies lacking internal manufacturing capabilities. According to the Global Biologics CDMO Market Size is expected to be worth around US$ 84.9 Billion by 2034, growing at a CAGR of 15.7% between 2025 to 2034. As demand surges for reliable, agile, and scalable partners, Zydus' entry into this space positions it to tap into significant long-term growth opportunities and support innovation across the global biopharmaceutical landscape. About Zydus Zydus Lifesciences Ltd. with an overarching purpose of empowering people with freedom to live healthier and more fulfilled lives, is an innovative, global lifesciences company that discovers, develops, manufactures, and markets a broad range of healthcare therapies. The group employs 27,000 people worldwide, including 1,400 scientists engaged in R&D, and is driven by its mission to unlock new possibilities in lifesciences through quality healthcare solutions that impact lives. The group aspires to transform lives through path-breaking discoveries. Over the last decade, Zydus has introduced several innovative, first-in-class products in the market for treating unmet healthcare needs with vaccines, therapeutics, biologicals and biosimilars. For more details visit: About Agenus Agenus Inc. is a clinical-stage immuno-oncology company committed to developing immune therapies that effectively combat cancer. Leveraging proprietary scientific platforms, the company's pipeline includes multiple checkpoint antibody candidates, vaccines, and cell therapies. Headquartered in Lexington, MA, Agenus operates globally, driving innovations to bring better cancer treatments to patients. For more details visit: Forward-Looking Statements: This press release contains forward-looking statements. Such forward-looking statements are subject to risks and uncertainties that could cause actual results to differ materially from those projected. These risks and uncertainties include, but are not limited to, the successful integration of the acquired business, market conditions, and other factors. Sujatha Rajesh (Media Relations), Zydus Lifesciences Limited, +91-9974051180 Arvind Bothra (Investor Relations), Zydus Lifesciences Limited, +91-7045656895
